Hearing on “Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling,” Subcommittee on Health (April 1, 2014)
The Subcommittee on Health held a hearing on Tuesday, April 1, 2014, at 3:00 p.m. in 2322 Rayburn House Office Building. The hearing was entitled “Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling.”
Opening Statement of Ranking Member Henry A. Waxman, as prepared for delivery.
Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration (FDA)
Michael D. Shumsky
Kirkland & Ellis LLP
Ralph G. Neas
President and CEO
Generic Pharmaceutical Association
Allison M. Zieve